Statement 26 June 2020

IFPMA Statement – Access to COVID-19 Tools Accelerator (ACT-Accelerator) Investment Case


Geneva, 26 June 2020: Today, we face the first global pandemic in living memory; affecting hundreds of millions of people around the world. Never before has there been so much hope placed in finding safe and effective vaccines, produced in sufficient quantities; with the promise to ensure no one is left behind.

IFPMA’s members, which include the leading innovative biopharmaceutical companies in the vaccine field, are working at unparalleled speed to develop vaccines and build manufacturing capacity and distribution networks to deploy a COVID-19 vaccine in record time. The pace and progress of this work is unprecedented.

We are proud to be a founding partner of the ACT-Accelerator and are fully committed to the goal of the COVAX pillar to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.

Access to COVID-19 vaccines is a collective responsibility that calls for highly coordinated and collaborative action by public and private actors alike and global solidarity to end the COVID-19 pandemic


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster